This article refers to ‘Efcacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clini- cal Trial (ATTR-ACT) and long-term extension study’ by T. Damy et al.
<div><p></p><p>Placebo-controlled clinical trials are useful for identifying the dose of a drug cand...
Abstract This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, effic...
AIM: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis r...
Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor...
Background: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accu...
AIM: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis r...
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in...
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal disorder resultin...
BACKGROUND: Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloi...
Objectives: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), ...
Transthyretin amyloidosis is a rare, life-threatening disease resulting from aggregation and deposit...
BACKGROUND: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardi...
Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have ...
Abstract Introduction In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT; Cli...
Tafamidis inhibits progression of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) by binding TT...
<div><p></p><p>Placebo-controlled clinical trials are useful for identifying the dose of a drug cand...
Abstract This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, effic...
AIM: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis r...
Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor...
Background: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accu...
AIM: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis r...
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in...
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal disorder resultin...
BACKGROUND: Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloi...
Objectives: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), ...
Transthyretin amyloidosis is a rare, life-threatening disease resulting from aggregation and deposit...
BACKGROUND: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardi...
Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have ...
Abstract Introduction In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT; Cli...
Tafamidis inhibits progression of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) by binding TT...
<div><p></p><p>Placebo-controlled clinical trials are useful for identifying the dose of a drug cand...
Abstract This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, effic...
AIM: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis r...
DOI
Add to ORKG